BACKGROUND: A study was undertaken to determine the effectiveness of asthma self-management in general practice. METHODS:Nineteen general practices were randomly allocated to usual care (UC) or self-management (SM). Asthma patients were included after confirmation of the GP diagnosis. Follow up was 2 years. Patients kept diary cards and visited the lung function laboratory every 6 months. Outcomes were number of successfully treated weeks, limited activity days, asthma specific quality of life, forced expiratory volume in 1 second (FEV(1)), FEV(1) reversibility, concentration of histamine provoking a fall in FEV(1) of 20% or more (PC(20) histamine), and amount of inhaled steroids. RESULTS: A total of 214 patients were included in the study (104 UC/110 SM; one third of the total asthma population in general practice); 62% were female. The mean percentage of successfully treated weeks per patient in the UC group was 72% (74/103 weeks) compared with 78% (81/105 weeks) in the SM group (p=0.003). The mean number of limited activity days was 1.2 (95% CI 0.5 to 1.9) in the SM group and 3.9 (95% CI 2.5 to 5.4) in the UC group. The estimated increase in asthma quality of life score was 0.10 points per visit in the UC group and 0.21 points per visit in the SM group (p=0.055). FEV(1), FEV(1) reversibility, and PC(20) histamine did not change. There was a saving of 217 puffs of inhaled steroid per patient in favour of the SM group (p<0.05). CONCLUSION: Self-management lowers the burden of illness as perceived by patients with asthma and is at least as effective as the treatment usually provided in Dutch primary care. Self-management is a safe basis for intermittent treatment with inhaled corticosteroids.
RCT Entities:
BACKGROUND: A study was undertaken to determine the effectiveness of asthma self-management in general practice. METHODS: Nineteen general practices were randomly allocated to usual care (UC) or self-management (SM). Asthmapatients were included after confirmation of the GP diagnosis. Follow up was 2 years. Patients kept diary cards and visited the lung function laboratory every 6 months. Outcomes were number of successfully treated weeks, limited activity days, asthma specific quality of life, forced expiratory volume in 1 second (FEV(1)), FEV(1) reversibility, concentration of histamine provoking a fall in FEV(1) of 20% or more (PC(20) histamine), and amount of inhaled steroids. RESULTS: A total of 214 patients were included in the study (104 UC/110 SM; one third of the total asthma population in general practice); 62% were female. The mean percentage of successfully treated weeks per patient in the UC group was 72% (74/103 weeks) compared with 78% (81/105 weeks) in the SM group (p=0.003). The mean number of limited activity days was 1.2 (95% CI 0.5 to 1.9) in the SM group and 3.9 (95% CI 2.5 to 5.4) in the UC group. The estimated increase in asthma quality of life score was 0.10 points per visit in the UC group and 0.21 points per visit in the SM group (p=0.055). FEV(1), FEV(1) reversibility, and PC(20) histamine did not change. There was a saving of 217 puffs of inhaled steroid per patient in favour of the SM group (p<0.05). CONCLUSION: Self-management lowers the burden of illness as perceived by patients with asthma and is at least as effective as the treatment usually provided in Dutch primary care. Self-management is a safe basis for intermittent treatment with inhaled corticosteroids.
Authors: I D Bijl-Hofland; H T Folgering; H van den Hoogen; S G Cloosterman; C Van Weel; J M Donkers; C P van Schayck Journal: Eur Respir J Date: 1999-11 Impact factor: 16.671
Authors: Bart P A Thoonen; Tjard R J Schermer; Margreet Jansen; Ivo Smeele; Annelies J E Jacobs; Richard Grol; Onno C P van Schayck Journal: Patient Educ Couns Date: 2002-08
Authors: Bart P A Thoonen; Tjard R J Schermer; Reinier P Akkermans; Joost J den Otter; Richard Grol; Onno C P van Schayck Journal: Scand J Prim Health Care Date: 2002-03 Impact factor: 2.581
Authors: Cécile R L Boot; Jan H M M Vercoulen; Joost W J van der Gulden; Karin H Orbon; Jos M Rooijackers; Chris van Weel; Hans Th M Folgering Journal: Int Arch Occup Environ Health Date: 2005-10-12 Impact factor: 3.015
Authors: Marjolein P de Vries; Lisette van den Bemt; Karen Aretz; Bart P A Thoonen; Jean W M Muris; Arnold D M Kester; Sonja Cloosterman; C P Onno van Schayck Journal: Br J Gen Pract Date: 2007-03 Impact factor: 5.386
Authors: Bernd Brüggenjürgen; Dagmar Selim; Peter Kardos; Kai Richter; Claus Vogelmeier; Stephanie Roll; Wolfgang Meyer-Sabellek; Roland Buhl; Stefan N Willich Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981
Authors: Meyer Balter; Pierre Ernst; Wade Watson; Harold Kim; Lisa Cicutto; Marie-France Beauchesne; Andrew J Cave; Alan Kaplan; Donna Hogg; Andrew McIvor; Tom Smiley; Michel Rouleau; J Mark FitzGerald Journal: Can Respir J Date: 2008 Nov-Dec Impact factor: 2.409